Emamgholipour Solaleh, Moradi Nariman, Beigy Maani, Shabani Parisa, Fadaei Reza, Poustchi Hossein, Doosti Mahmood
Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Department of Clinical Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Diabetol Metab Syndr. 2015 Nov 25;7:108. doi: 10.1186/s13098-015-0099-z. eCollection 2015.
It is well-established that nonalcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes mellitus (T2DM). Complement-C1q TNF-related protein 5 (CTRP5) is a novel adipokine involved in the regulation of lipid and glucose metabolism. We aimed to assess plasma levels of CTRP5 in patients with NAFLD (n = 22), T2DM (n = 22) and NAFLD with T2DM (NAFLD + T2DM) (n = 22) in comparison with healthy subjects (n = 21) and also to study the association between CTRP5 levels and NAFLD and diabetes-related parameters.
All subjects underwent anthropometric assessment, biochemical evaluation and liver stiffness (LS) measurement. Insulin resistance (IR) was determined by the homeostasis model assessment (HOMA). Plasma CTRP5 levels were measured by enzyme-linked immunosorbent assay.
We found significantly lower plasma levels of CTRP5 in patients with NAFLD + T2DM, NAFLD and T2DM (122.52 ± 1.92, 124.7 ± 1.82 and 118.31 ± 1.99 ng/ml, respectively) in comparison with controls (164.96 ± 2.95 ng/ml). In the whole study population, there was a significant negative correlations between CTRP5 and body mass index (r = -0.337; p = 0.002), fasting blood glucose (FBG) (r = -0.488; p < 0.001), triglyceride (TG) (r = -0.245; p = 0.031), HOMA-IR (r = -0.492; p < 0.001), insulin(r = -0.338; p = 0.002), LS (r = -0.544; p < 0.001), alanine aminotransferase (ALT) (r = -0.251; p = 0.027), waist-to-hip ratio (WHR) (r = -0.352; p = 0.002) and waist circumference (WC) (r = -0.357; p = 0.001). After adjustment for BMI, decrease in circulating levels of CTRP5 remained as a significant risk factor for NAFLD, T2DM and NAFLD + T2DM. The receiver operating characteristic (ROC) curves of circulating CTRP5 in predicting NAFLD and T2DM demonstrated an area under the curve (AUC) of 0.763 in T2DM, and 0.659 in NAFLD + T2DM.
It appears that the decreased levels of CTRP5 contribute to the increased risk of T2DM and NAFLD.
非酒精性脂肪性肝病（NAFLD）与2型糖尿病（T2DM）相关，这一点已得到充分证实。补体C1q肿瘤坏死因子相关蛋白5（CTRP5）是一种新型脂肪因子，参与脂质和葡萄糖代谢的调节。我们旨在评估非酒精性脂肪性肝病患者（n = 22）、2型糖尿病患者（n = 22）和合并2型糖尿病的非酒精性脂肪性肝病（NAFLD + T2DM）患者（n = 22）血浆CTRP5水平，并与健康受试者（n = 21）进行比较，同时研究CTRP5水平与非酒精性脂肪性肝病及糖尿病相关参数之间的关联。
所有受试者均接受人体测量评估、生化评估及肝脏硬度（LS）测量。通过稳态模型评估（HOMA）确定胰岛素抵抗（IR）。采用酶联免疫吸附测定法测量血浆CTRP5水平。
我们发现，与对照组（164.96±2.95 ng/ml）相比，NAFLD + T2DM、NAFLD和T2DM患者的血浆CTRP5水平显著降低（分别为122.52±1.92、124.7±1.82和118.31±1.99 ng/ml）。在整个研究人群中，CTRP5与体重指数（r = -0.337；p = 0.002）、空腹血糖（FBG）（r = -0.488；p < 0.001）、甘油三酯（TG）（r = -0.245；p = 0.031）、HOMA-IR（r = -0.492；p < 0.001）、胰岛素（r = -0.338；p = 0.002）、LS（r = -0.544；p < 0.001）、丙氨酸氨基转移酶（ALT）（r = -0.251；p = 0.027）、腰臀比（WHR）（r = -0.352；p = 0.002）和腰围（WC）（r = -0.357；p = 0.001）之间存在显著负相关。在调整体重指数后，循环CTRP5水平降低仍然是NAFLD、T2DM和NAFLD + T2DM的显著危险因素。循环CTRP5预测NAFLD和T2DM的受试者工作特征（ROC）曲线显示，T2DM的曲线下面积（AUC）为0.763，NAFLD + T2DM为0.659。
CTRP5水平降低似乎会增加T2DM和NAFLD的发病风险。
